30.06 USD
-0.54 (-1.76%)
At close: Feb 11, 2026
29.77 USD
-0.29 (-0.96%)
After Hours: 2/11/2026, 8:27:40 PM
Overall GMAB gets a fundamental rating of 7 out of 10. We evaluated GMAB against 523 industry peers in the Biotechnology industry. GMAB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMAB is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, GMAB could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year GMAB was profitable.
- GMAB had a positive operating cash flow in the past year.
- GMAB had positive earnings in each of the past 5 years.
- GMAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of GMAB (21.10%) is better than 97.32% of its industry peers.
- Looking at the Return On Equity, with a value of 25.76%, GMAB belongs to the top of the industry, outperforming 96.94% of the companies in the same industry.
- The Return On Invested Capital of GMAB (17.11%) is better than 96.75% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for GMAB is below the industry average of 18.27%.
- The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
- With an excellent Profit Margin value of 41.35%, GMAB belongs to the best of the industry, outperforming 97.32% of the companies in the same industry.
- GMAB's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 36.85%, GMAB belongs to the best of the industry, outperforming 97.90% of the companies in the same industry.
- GMAB's Operating Margin has declined in the last couple of years.
- The Gross Margin of GMAB (94.27%) is better than 94.84% of its industry peers.
- In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, GMAB has less shares outstanding
- GMAB has less shares outstanding than it did 5 years ago.
- GMAB has a worse debt/assets ratio than last year.
2.2 Solvency
- GMAB has an Altman-Z score of 11.48. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of GMAB (11.48) is better than 83.56% of its industry peers.
- The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
- GMAB has a better Debt to FCF ratio (0.12) than 95.79% of its industry peers.
- A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
- GMAB has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: GMAB outperforms 43.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 11.48 |
ROIC/WACC2.34
WACC7.32%
2.3 Liquidity
- A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
- GMAB has a Current ratio of 6.03. This is in the better half of the industry: GMAB outperforms 63.10% of its industry peers.
- A Quick Ratio of 6.01 indicates that GMAB has no problem at all paying its short term obligations.
- With a decent Quick ratio value of 6.01, GMAB is doing good in the industry, outperforming 64.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
- GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.90%, which is quite impressive.
- The Earnings Per Share has been growing by 28.38% on average over the past years. This is a very strong growth
- Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
- The Revenue has been growing by 31.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
- Based on estimates for the next years, GMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.70% on average per year.
- The Revenue is expected to grow by 14.39% on average over the next years. This is quite good.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y11.7%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y14.39%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 12.74, GMAB is valued correctly.
- GMAB's Price/Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 97.32% of the companies in the same industry.
- GMAB's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.23.
- GMAB is valuated rather expensively with a Price/Forward Earnings ratio of 17.66.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 93.88% of the companies listed in the same industry.
- GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.01.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.74 | ||
| Fwd PE | 17.66 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.32% of the companies listed in the same industry.
- GMAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.38 | ||
| EV/EBITDA | 10.05 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of GMAB may justify a higher PE ratio.
PEG (NY)1.98
PEG (5Y)0.45
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
5. Dividend
5.1 Amount
- GMAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
30.06
-0.54 (-1.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-05 2026-02-05/amc
Earnings (Next)05-07 2026-05-07
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.52B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts73.08
Price Target47.44 (57.82%)
Short Float %1.68%
Short Ratio6.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.34%
EPS NQ rev (3m)2.2%
EPS NY rev (1m)3.51%
EPS NY rev (3m)7.6%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-0.85%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.74 | ||
| Fwd PE | 17.66 | ||
| P/S | 5.17 | ||
| P/FCF | 15.38 | ||
| P/OCF | 14.53 | ||
| P/B | 3.22 | ||
| P/tB | 5.08 | ||
| EV/EBITDA | 10.05 |
EPS(TTM)2.36
EY7.85%
EPS(NY)1.7
Fwd EY5.66%
FCF(TTM)1.95
FCFY6.5%
OCF(TTM)2.07
OCFY6.88%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)1.98
PEG (5Y)0.45
Graham Number22.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 11.48 |
F-Score7
WACC7.32%
ROIC/WACC2.34
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y11.7%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y14.39%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 7 / 10 to GMAB.
What is the valuation status for GMAB stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for GMAB stock?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 12.74 and the Price/Book (PB) ratio is 3.22.
Can you provide the financial health for GMAB stock?
The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.